Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
pharmaphorum21h
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2024 Update
Kenneth Fisher's 13F portfolio grows to $251B in Q4 2024, with top holdings in Apple, Nvidia, Microsoft, Amazon, and Alphabet ...